Share Facebook Twitter Email Telegram WhatsApp Yet so far, research facilities produce vastly inconsistent results on how the body will react to them…Read More
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines AgencyJanuary 28, 2023